This morning OptiBiotix Health Plc (AIM: OPTI) released significant news that they have signed a major manufacturing, supply and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.

The Share Talk team took the opportunity to speak with Stephen O'Hara the serial entrepreneur, CEO and founder of OptiBiotix Health Plc. #OPTI is a life sciences company operating in one of the most progressive areas of biotechnological research - the modulation of the human microbiome.

In our interview, Stephen gives an overview of the company; how he started OPTI in 2012 and took it from the laboratory to listing on AIM in August 2014, after the shares were placed at 8p. He explains the needs and benefits of modifying the human microbiome and the health benefits of OPTI's range of products. He also describes the growing awareness of OPTI's technology platforms: Optibiotics®, OptiScreen®, SkinBiotix ® and products SlimBiome® LP-LDL™ and the rapid rise in the number of patents that OPTI presently holds.

Stephen explains the methodical and thoughtful strategy that he and his team at OPTI have put in place, to enable the innovative and disruptive technologies and products they have in their pipeline to continue to grow successfully worldwide.

With the OPTI shares up 3% at 74.5p, listen now to Stephen O'Hara, CEO of OptiBiotix Health Plc speaking about OPTI's manufacturing, supply and profit sharing deal with Sacco and their global plans for LP-LDL™.